---
provider: asta
model: Asta Scientific Corpus Retrieval
cached: false
start_time: '2026-10-28T14:15:36.394794'
end_time: '2026-10-28T14:16:01.718913'
duration_seconds: 25.32
template_file: templates/hypothesis_deep_research.md
template_variables:
  disease_name: Alzheimer Disease
  category: Neurodegenerative Disorder
  hypothesis_group_id: d2r_arrestin_gsk3b_tau_model
  hypothesis_label: D2 Receptor-Arrestin-GSK-3beta Tau Kinase Model
  hypothesis_status: EMERGING
  hypothesis_yaml: "hypothesis_group_id: d2r_arrestin_gsk3b_tau_model\nhypothesis_label:\
    \ D2 Receptor-Arrestin-GSK-3beta Tau Kinase Model\nstatus: EMERGING\ndescription:\
    \ 'Tau phosphorylation in Alzheimer disease is modeled as partly set by the signalling\
    \ state\n  of D2-family dopamine receptors, making a D2/D3 partial agonist a candidate\
    \ disease-modifying rather\n  than purely symptomatic agent. D2 receptor over-activation\
    \ drives the beta-arrestin2/PP2A/Akt scaffold\n  toward Akt dephosphorylation,\
    \ which relieves inhibitory Ser9 phosphorylation on GSK-3beta, the principal\n\
    \  tau kinase. Aripiprazole, unlike the full antagonist haloperidol, preserves\
    \ phospho-Akt and phospho-GSK-3beta\n  under D2R hyperactivity in cortical neurons,\
    \ and is a weak-partial or frankly antagonist ligand at D2/D3-mediated\n  beta-arrestin\
    \ translocation. The model is significant because it predicts a readout nobody\
    \ has measured:\n  if it holds, chronic aripiprazole exposure should lower tau\
    \ phosphorylation at GSK-3beta-dependent epitopes\n  in a tauopathy model, and\
    \ the existing beta-arrestin-biased aripiprazole analogue UNC9994 should fail\n\
    \  to reproduce the effect or reverse it.'\nevidence:\n- reference: PMID:30597182\n\
    \  reference_title: Aripiprazole and haloperidol protect neurite lesions via reducing\
    \ excessive D2R-DISC1\n    complex formation.\n  supports: SUPPORT\n  directness:\
    \ INDIRECT\n  evidence_source: IN_VITRO\n  snippet: Unlike haloperidol, aripiprazole\
    \ prevented downregulation of phospho (p) Akt-pGSK3\u03B2 induced\n    by D2R\
    \ hyperactivity, indicating involvement of different pathways.\n  explanation:\
    \ The load-bearing result. It places aripiprazole upstream of Akt-GSK-3beta signalling\
    \ in\n    cortical neurons and distinguishes it from a full D2 antagonist, which\
    \ is what makes the model a claim\n    about this drug rather than about antipsychotics\
    \ as a class. Indirect because the readout is neurite\n    morphology in a neurodevelopmental\
    \ model, not tau.\n- reference: PMID:41192583\n  reference_title: Distinct functional\
    \ profiles of partial agonist antipsychotics in cAMP and \u03B2-arrestin\n   \
    \ signaling mechanisms of dopamine D(2) and D(3) receptors in vitro.\n  supports:\
    \ SUPPORT\n  directness: INDIRECT\n  evidence_source: IN_VITRO\n  snippet: aripiprazole\
    \ and brexpiprazole displayed only weak or no agonist but potent antagonist activity\n\
    \  explanation: Characterizes the arrestin-pathway ligand profile the model depends\
    \ on, at recombinant\n    human D3 receptors. A drug that antagonizes arrestin\
    \ recruitment is positioned to prevent the arrestin-dependent\n    Akt dephosphorylation\
    \ this model invokes.\n- reference: PMID:39174788\n  reference_title: Administration\
    \ of Aripiprazole Alleviates Memory Impairment and Restores Damaged Glutamatergic\n\
    \    System in 5xFAD Mice.\n  supports: SUPPORT\n  directness: INDIRECT\n  evidence_source:\
    \ MODEL_ORGANISM\n  snippet: The aripiprazole-treated group exhibited alleviated\
    \ memory impairment in a novel object recognition\n    test.\n  explanation: The\
    \ only in vivo exposure of an Alzheimer model to chronic aripiprazole, establishing\
    \ that\n    the drug is not behaviourally inert in an amyloid model at 1 mg/kg/day.\
    \ It supports the premise rather\n    than the route - the mechanism the authors\
    \ report is glutamatergic, and neither tau nor GSK-3beta\n    was measured.\n\
    - reference: PMID:34173272\n  reference_title: 'Long-term antipsychotic use and\
    \ cognitive decline in community-dwelling older adults\n    with mild-moderate\
    \ Alzheimer disease: Data from NILVAD.'\n  supports: REFUTE\n  directness: INDIRECT\n\
    \  evidence_source: HUMAN_CLINICAL\n  snippet: Long-term antipsychotic use was\
    \ associated with greater cognitive decline and dementia progression\n    in community-dwelling\
    \ older adults with mild-moderate AD.\n  explanation: The principal human counter-evidence,\
    \ and the constraint any disease-modifying reading\n    has to survive. Indirect\
    \ because the exposure is drug-class-level rather than aripiprazole-specific\n\
    \    and the design is observational within a trial cohort, so confounding by\
    \ indication is unresolved\n    - neuropsychiatric symptoms themselves predict\
    \ faster decline.\nnotes: 'EMERGING, and declared here to scope a deep-research\
    \ exploration rather than to assert a curated\n  mechanism. Nothing in this entry''s\
    \ pathograph opts into this group yet, and no causal edge should until\n  the\
    \ tau arm has direct support. The route is assembled from cross-domain work: the\
    \ Akt-GSK-3beta result\n  is in cortical neurons in a schizophrenia/DISC1 context,\
    \ the ligand profiling is in recombinant cell\n  lines, and the only Alzheimer-model\
    \ exposure reports a glutamatergic readout. An earlier version of\n  this note\
    \ claimed no study had measured tau after aripiprazole in an Alzheimer model;\
    \ that was wrong,\n  and PMID:32587124 is the counterexample - GSK-3beta, acetylated\
    \ tau and phospho-tau in APP-Swedish N2a\n  cells, with aripiprazole in a three-drug\
    \ combination, attributed to SIRT1 rather than to arrestin. The\n  prediction\
    \ is therefore weakly probed and confounded rather than untested, and the open\
    \ experiment is\n  to isolate aripiprazole in vivo. The premise may also need\
    \ inverting: the prevailing Alzheimer dopamine\n  framework is VTA hypodopaminergia\
    \ (PMID:28367951), not D2 over-activation, and a partial agonist restoring\n \
    \ dopaminergic tone would explain the same drug-level results. See the assessment\
    \ sidecar under kb/hypotheses/\n  for the full review. Three things should be\
    \ checked before this is promoted: whether the pAkt-pGSK-3beta\n  preservation\
    \ reproduces in neurons carrying tau pathology; whether the beta-arrestin-biased\
    \ aripiprazole\n  analogue UNC9994 separates the arrestin-blocking reading from\
    \ a biased-signalling one; and whether the\n  NILVAD class-level signal survives\
    \ a drug-specific and dose-stratified analysis, given that therapeutic-dose\n\
    \  D2 occupancy is far above the exposure used in the 5xFAD study.'"
  artifact_dir: kb/hypotheses/Alzheimer_Disease/d2r_arrestin_gsk3b_tau_model/asta_artifacts
provider_config:
  timeout: null
  max_retries: 3
  parameters:
    allowed_domains: []
    query_char_limit: 500
    paper_limit: 50
    snippet_limit: 20
    snippet_paper_limit: 50
    restrict_snippets_to_papers: false
    paper_fields: title,abstract,authors,year,url,venue,journal,tldr,publicationDate,citationCount,influentialCitationCount,externalIds
    publication_date_range: ''
    venues: ''
    inserted_before: ''
citation_count: 19
term_validation:
  total_terms: 0
  verified: 0
  not_found: 0
  obsolete: 0
  unverifiable: 0
  confabulation_rate: 0.0
  adapter: 'ols:'
  validator_version: 0.4.5
---

## Question

# Mechanistic Hypothesis Search

You are evaluating a specific disease mechanism hypothesis for the Disorder
Mechanisms Knowledge Base. This is not a general disease overview. Use the
hypothesis YAML below as the seed claim, then search for evidence that supports,
refutes, qualifies, or competes with this hypothesis.

## Target Disease
- **Disease Name:** Alzheimer Disease
- **Category:** Neurodegenerative Disorder

## Target Hypothesis
- **Hypothesis ID:** d2r_arrestin_gsk3b_tau_model
- **Hypothesis Label:** D2 Receptor-Arrestin-GSK-3beta Tau Kinase Model
- **Status in KB:** EMERGING

## Seed Hypothesis YAML

```yaml
hypothesis_group_id: d2r_arrestin_gsk3b_tau_model
hypothesis_label: D2 Receptor-Arrestin-GSK-3beta Tau Kinase Model
status: EMERGING
description: 'Tau phosphorylation in Alzheimer disease is modeled as partly set by the signalling state
  of D2-family dopamine receptors, making a D2/D3 partial agonist a candidate disease-modifying rather
  than purely symptomatic agent. D2 receptor over-activation drives the beta-arrestin2/PP2A/Akt scaffold
  toward Akt dephosphorylation, which relieves inhibitory Ser9 phosphorylation on GSK-3beta, the principal
  tau kinase. Aripiprazole, unlike the full antagonist haloperidol, preserves phospho-Akt and phospho-GSK-3beta
  under D2R hyperactivity in cortical neurons, and is a weak-partial or frankly antagonist ligand at D2/D3-mediated
  beta-arrestin translocation. The model is significant because it predicts a readout nobody has measured:
  if it holds, chronic aripiprazole exposure should lower tau phosphorylation at GSK-3beta-dependent epitopes
  in a tauopathy model, and the existing beta-arrestin-biased aripiprazole analogue UNC9994 should fail
  to reproduce the effect or reverse it.'
evidence:
- reference: PMID:30597182
  reference_title: Aripiprazole and haloperidol protect neurite lesions via reducing excessive D2R-DISC1
    complex formation.
  supports: SUPPORT
  directness: INDIRECT
  evidence_source: IN_VITRO
  snippet: Unlike haloperidol, aripiprazole prevented downregulation of phospho (p) Akt-pGSK3β induced
    by D2R hyperactivity, indicating involvement of different pathways.
  explanation: The load-bearing result. It places aripiprazole upstream of Akt-GSK-3beta signalling in
    cortical neurons and distinguishes it from a full D2 antagonist, which is what makes the model a claim
    about this drug rather than about antipsychotics as a class. Indirect because the readout is neurite
    morphology in a neurodevelopmental model, not tau.
- reference: PMID:41192583
  reference_title: Distinct functional profiles of partial agonist antipsychotics in cAMP and β-arrestin
    signaling mechanisms of dopamine D(2) and D(3) receptors in vitro.
  supports: SUPPORT
  directness: INDIRECT
  evidence_source: IN_VITRO
  snippet: aripiprazole and brexpiprazole displayed only weak or no agonist but potent antagonist activity
  explanation: Characterizes the arrestin-pathway ligand profile the model depends on, at recombinant
    human D3 receptors. A drug that antagonizes arrestin recruitment is positioned to prevent the arrestin-dependent
    Akt dephosphorylation this model invokes.
- reference: PMID:39174788
  reference_title: Administration of Aripiprazole Alleviates Memory Impairment and Restores Damaged Glutamatergic
    System in 5xFAD Mice.
  supports: SUPPORT
  directness: INDIRECT
  evidence_source: MODEL_ORGANISM
  snippet: The aripiprazole-treated group exhibited alleviated memory impairment in a novel object recognition
    test.
  explanation: The only in vivo exposure of an Alzheimer model to chronic aripiprazole, establishing that
    the drug is not behaviourally inert in an amyloid model at 1 mg/kg/day. It supports the premise rather
    than the route - the mechanism the authors report is glutamatergic, and neither tau nor GSK-3beta
    was measured.
- reference: PMID:34173272
  reference_title: 'Long-term antipsychotic use and cognitive decline in community-dwelling older adults
    with mild-moderate Alzheimer disease: Data from NILVAD.'
  supports: REFUTE
  directness: INDIRECT
  evidence_source: HUMAN_CLINICAL
  snippet: Long-term antipsychotic use was associated with greater cognitive decline and dementia progression
    in community-dwelling older adults with mild-moderate AD.
  explanation: The principal human counter-evidence, and the constraint any disease-modifying reading
    has to survive. Indirect because the exposure is drug-class-level rather than aripiprazole-specific
    and the design is observational within a trial cohort, so confounding by indication is unresolved
    - neuropsychiatric symptoms themselves predict faster decline.
notes: 'EMERGING, and declared here to scope a deep-research exploration rather than to assert a curated
  mechanism. Nothing in this entry''s pathograph opts into this group yet, and no causal edge should until
  the tau arm has direct support. The route is assembled from cross-domain work: the Akt-GSK-3beta result
  is in cortical neurons in a schizophrenia/DISC1 context, the ligand profiling is in recombinant cell
  lines, and the only Alzheimer-model exposure reports a glutamatergic readout. An earlier version of
  this note claimed no study had measured tau after aripiprazole in an Alzheimer model; that was wrong,
  and PMID:32587124 is the counterexample - GSK-3beta, acetylated tau and phospho-tau in APP-Swedish N2a
  cells, with aripiprazole in a three-drug combination, attributed to SIRT1 rather than to arrestin. The
  prediction is therefore weakly probed and confounded rather than untested, and the open experiment is
  to isolate aripiprazole in vivo. The premise may also need inverting: the prevailing Alzheimer dopamine
  framework is VTA hypodopaminergia (PMID:28367951), not D2 over-activation, and a partial agonist restoring
  dopaminergic tone would explain the same drug-level results. See the assessment sidecar under kb/hypotheses/
  for the full review. Three things should be checked before this is promoted: whether the pAkt-pGSK-3beta
  preservation reproduces in neurons carrying tau pathology; whether the beta-arrestin-biased aripiprazole
  analogue UNC9994 separates the arrestin-blocking reading from a biased-signalling one; and whether the
  NILVAD class-level signal survives a drug-specific and dose-stratified analysis, given that therapeutic-dose
  D2 occupancy is far above the exposure used in the 5xFAD study.'
```

## Research Objective

Build a focused hypothesis-search report that answers:

1. What is the strongest direct evidence for this hypothesis?
2. What evidence argues against it, fails to reproduce it, or limits its scope?
3. Which claims are established, emerging, speculative, or contradicted?
4. Which patient subtypes, stages, tissues, cell types, molecular pathways, or
   biomarkers does the hypothesis best explain?
5. Which alternative or competing mechanistic hypotheses explain the same disease
   features better or more parsimoniously?
6. What are the explicit knowledge gaps: missing causal steps, unconfirmed edges,
   contradictory evidence, unknown source-to-target links, or source/data absences?
7. What experiments, cohorts, assays, datasets, or trials would most directly
   distinguish this hypothesis from alternatives?

Use primary literature whenever possible. Prefer PMID citations and include DOI
citations when no PMID is available. Treat reviews as orientation unless they
contain directly relevant synthesized evidence that should be clearly labeled as
review-level support.

When dataset or scientific-tool access is available, use it for questions that
can be tested computationally rather than limiting the run to literature search.
Preflight the required data lake, databases, packages, credentials, and tools
before claiming that an analysis can run. Never silently fall back from a failed
dataset/tool analysis to literature synthesis or model knowledge: report the
failure, the fallback, and the resulting limitation explicitly. A proposed
analysis must never be described as performed.

## Required Output

### Executive Judgment

Give a concise verdict on the hypothesis as of the current literature:
supported, partially supported, unresolved, weakly supported, or refuted. Explain
the reasoning and the most important caveats.

### Evidence Matrix

Create a table with one row per important evidence item:

- Citation (PMID preferred)
- Evidence type (human clinical, model organism, in vitro, computational, review)
- Supports / refutes / qualifies / competing
- Mechanistic claim tested
- Key finding
- Disease subtype or context
- Confidence and limitations

### Data and Tool Use

Inventory every dataset, database, API, supplementary file, or local input
material to the report. For each, state:

- stable accession or URI, repository/source, version or snapshot, and retrieval
  date where known;
- whether it was only cited/proposed, actually accessed, searched with no usable
  result, or could not be verified;
- the exact query, filters, cohort, sample subset, organism, tissue, assay, and
  comparison used where applicable;
- whether the accession resolved and whether its subject matter is genuinely
  relevant to this disease and hypothesis.

For accessed sources and negative searches, save a sanitized query response,
input manifest, or search log in the provider artifact bundle; prose alone does
not establish access or a negative result.

Inventory each attempted analysis separately. Trace input -> method -> output,
including software/model versions, material parameters, code or workflow,
environment, random seeds where relevant, output files, and limitations. Label
the execution outcome as succeeded, partial, failed, skipped, or reported-only.
Do not count a prose assertion without inspectable execution evidence as a
successful analysis.

### Mechanistic Causal Chain

Describe the causal chain implied by the hypothesis from upstream trigger to
clinical manifestation. Identify where the literature is strong, where the links
are inferred, and where there are missing causal steps.

### Knowledge Gaps

Identify explicit known unknowns surfaced by the search. Treat absence of
evidence as a curation-relevant finding only when the search actually checked for
it. Include:

- Unknown or weakly supported causal steps in the hypothesis
- Unconfirmed causal graph edges that need direct perturbation or longitudinal
  evidence
- Conflicting evidence, failed replications, or incompatible subtype-specific
  findings
- Unknown mechanism of action for relevant treatments, biomarkers, or
  interventions tied to this hypothesis
- Source-level or dataset-level absences, such as no relevant GenCC, ClinGen,
  trial, omics, or cohort evidence found as of the search date

For each gap, state the scope, why it matters, what was checked, and what
evidence or experiment would resolve it. A negative database search must include
the database/version, query, filters, and search date; otherwise label it
unverified rather than claiming absence.

### Alternative Models

List competing or complementary hypotheses. For each, explain whether it is an
alternative to the seed hypothesis, a downstream consequence, an upstream cause,
or a parallel mechanism.

### Discriminating Tests

Recommend concrete studies or assays that would most efficiently test this
hypothesis against alternatives. Include patient stratification, biomarkers,
sample type, model system, perturbation, and expected result where applicable.

### Curation Leads

Provide candidate updates for the KB, but label these as leads requiring curator
verification. Include:

- candidate evidence references and exact abstract snippets to verify
- candidate pathophysiology nodes or edges
- candidate ontology terms for cell types and biological processes
- candidate subtype restrictions or status changes
- candidate `knowledge_gaps` or discussion prompts for unresolved causal claims,
  conflicting evidence, or explicit source/data absences

If the provider supports artifacts, produce a provider artifact bundle containing
canonical `MANIFEST.yaml` (schema version, status/fallback flags, checksummed
inputs/outputs, and replay verification), code/query/configuration, an
environment or package-version record,
sanitized execution logs, and small derived tables/figures needed to inspect the
result beneath `kb/hypotheses/Alzheimer_Disease/d2r_arrestin_gsk3b_tau_model/asta_artifacts`. Do not create an empty bundle when no data
source was accessed and no analysis ran. Give each artifact a stable relative
path and connect computed claims to their input, method, and output artifacts.
Do not bundle large recoverable raw
downloads, a provider data lake, controlled/patient-level data, credentials, or
signed URLs; record their stable external identifiers, versions, and checksums
instead. State explicitly when an expected artifact is external, local-only,
missing, or was not produced.


## Output

# Asta Literature Retrieval: Mechanistic Hypothesis Search You are evaluating a specific disease mechanism hypothesis for the Disorder Mechanisms...

This report is retrieval-only and is generated directly from Asta results.

- Papers retrieved: 19
- Snippets retrieved: 20

## Relevant Papers

### [1] Alzheimer's disease is TH17 related autoimmune disease against misfolded beta amyloid
- Authors: Wan-Jiung Hu
- Year: 2011
- Venue: Nature Precedings
- URL: https://www.semanticscholar.org/paper/f3135072d15a6f38dce26e7e866f172eb2c76e6e
- DOI: 10.1038/NPRE.2011.5934.3
- Citations: 4
- Summary: The immune-amyloid hypothesis is proposed as a mechanism for Alzheimer's disease, where accumulation of misfolded beta amyloid can trigger heat shock protein which in turn induces TH17 immunity.
- Evidence snippets:
  - Snippet 1 (score: 0.696)
    > Alzheimer's disease is a common neurodegenerative disorder. However, its exact etiology is still unknown. There were several mechanisms proposed such as the tau hypothesis and amyloid hypothesis. However, there is evidence challenging the above two hypotheses. Here, I propose the immune-amyloid hypothesis as a mechanism for Alzheimer's disease. Th17 related autoimmunity contributes to the disease pathogenesis. Accumulation of misfolded beta amyloid can trigger heat shock protein which in turn induces TH17 immunity. By microarray analysis of peripheral blood mononuclear cells, there is up-regulation of many TH17 related molecules after Alzheimer's disease. After knowing the exact disease pathogenesis, we can develop new therapeutic strategies to prevent or treat the detrimental disorder.

### [2] ARSA: an autonomous research scientist for target nomination in Alzheimer’s disease and related dementias
- Authors: Xue-Yang Li, Jia-Hui Liu, Jian-Nan Liu, Timothy I. Richardson, J. Dage et al.
- Year: 2026
- Venue: bioRxiv
- URL: https://www.semanticscholar.org/paper/9f8a088b1134f0f2edea73c31fad5eee18951f11
- DOI: 10.64898/2026.09.19.752836
- Summary: ARSA, an autonomous research scientist that transforms natural-language research interests and molecular data into prioritized, evidence-grounded target shortlists, enables systematic, transparent target exploration, opening opportunities to broaden the therapeutic mechanisms investigated in ADRD.
- Evidence snippets:
  - Snippet 1 (score: 0.693)
    > Alzheimer's disease and related dementias (ADRD) impose a substantial global burden, with an estimated 57 million people living with dementia in 2021 [1]. Despite progress with anti-amyloid treatment in early Alzheimer's disease (AD) [2], expanding the range of therapeutic mechanisms remains a major priority [3]. Target nomination connects disease biology to therapeutic development by identifying and prioritizing molecular candidates for experimental validation and drug discovery [4]. These upstream decisions direct subsequent research investment [5], and their importance is reflected in the greater clinical success of drug mechanisms supported by human genetic evidence [6]. A more systematic and efficient approach to nominating biologically grounded targets could therefore accelerate early-stage ADRD drug discovery and broaden the mechanisms advanced for therapeutic investigation.
    > However, developing a defensible target nomination remains a labor-intensive process that requires coordination across multiple disciplines [4]. Researchers must review published studies, formulate mechanistic hypotheses, analyze molecular data, and assemble evidence for a candidate's disease relevance and therapeutic tractability. Implementing these analyses requires programming and statistical expertise [7], while interpreting their therapeutic implications draws on disease biology, structural biology, pharmacology, and medicinal chemistry [4]. The capacity to investigate new candidates therefore depends not only on access to data, but also on access to specialized expertise and the time required to coordinate these activities. In ADRD, this work is further complicated by the need to reconcile cohort-specific clinical and pathological definitions [8,9], interpret molecular changes in their cellular and anatomical contexts [10,11], and weigh discordant transcriptomic and proteomic evidence [12]. Evidence platforms such as Open Targets [13] make relevant information accessible, but investigators must still determine which analyses to perform and how the combined evidence supports a nomination. This dependence on manual analysis planning Claim-level auditing supports refinement and reassessment, followed by hypothesis ranking and user selection. c, The selected hypothesis and harmonized dataset context guide evidence-centered planning and execution. Code repair addresses execution failures, while reflection after each step determines whether to proceed, revise, backtrack, or terminate the investigation (termination branch not shown). Completed analyses yield initial candidate genes.

### [3] Traditional Chinese medicine’s holistic approach: regulating microglia-driven neuroinflammation for the resolution of Alzheimer’s disease
- Authors: Jialing Yu, Xinya Bao, Chuchu Shan, Ze-Bin Yu, Ya-Jie Yu et al.
- Year: 2025
- Venue: Frontiers in Cellular Neuroscience
- URL: https://www.semanticscholar.org/paper/bab92db65d7e557e97f5a4147c1bef1249ebc12c
- DOI: 10.3389/fncel.2025.1691253
- PMID: 41256774
- PMCID: 12620364
- Citations: 3
- Summary: The key role of microglia-mediated neuroinflammation in the pathogenesis of AD is reviewed and traditional Chinese medicine demonstrates potential in intervening in AD neuroinflammation by regulating the microglial phenotype and function.
- Evidence snippets:
  - Snippet 1 (score: 0.693)
    > A systematic literature search was conducted in the following electronic databases from January 2000 to June 2025: PubMed, Web of Science Core Collection, and the China National Knowledge Infrastructure (CNKI). The search strategy utilized a combination of Medical Subject Headings (MeSH) terms and free-text keywords related to three core concepts: (1) Alzheimer's disease, (2) microglia and neuroinflammation, and (3) TCM. The specific search string for PubMed was as follows: ("Alzheimer Disease" OR "Alzheimer's Disease") AND ("Microglia" OR "Neuroinflammation" OR "Microglial Polarization") AND ("Medicine, Chinese Traditional" OR "Traditional Chinese Medicine" OR "Herbal Medicine" OR "Chinese Herbs" OR specific herb names such as "Ginseng" OR "Ginkgo biloba").
    > Similar strategies were adapted for the syntax requirements of other databases (Web of Science and CNKI). Additionally, the reference lists of the retrieved relevant review articles and primary studies were manually screened to identify any potentially eligible publications that might have been missed in the database search.
    > 3 The central role of microglial polarization regulation in Alzheimer's disease AD, characterized by cognitive dysfunction, motor abnormalities, and memory disorders, is a progressive neurodegenerative disease. Its development is divided into three stages: preclinical, mild cognitive impairment (MCI), and dementia. Alzheimer's disease has three key pathological features: the extracellular deposition of Aβ, the accumulation of NFTs throughout the brain, and neuroinflammation. The accuracy of Aβ as a biomarker for AD in the amyloid hypothesis proposed two decades ago has been seriously challenged. Studies have found Aβ in approximately 30% of cognitively normal older individuals, and the strategy of clearing Aβ to treat AD has also been disappointing, indicating that the "amyloid cascade hypothesis" cannot fully explain the molecular mechanisms of AD pathogenesis. In addition to amyloid hypothesis, oxidative stress hypothesis, cholinergic hypothesis, and neuroinflammation hypothesis provide multiple angles for studying the pathogenesis of AD.

### [4] A philosophy of science approach to the amyloid hypothesis of Alzheimer's disease
- Authors: T. Daly
- Year: 2024
- Venue: European Journal of Neuroscience
- URL: https://www.semanticscholar.org/paper/5e71a0b039c108893656dc2a85ca5b8818560d2f
- DOI: 10.1111/ejn.16500
- PMID: 39119857
- Citations: 10
- Summary: It is argued that philosophy of science can improve the chance of constructive debate by giving researchers technical language to describe and assess scientific progress by interpreting the amyloid hypothesis using a modified version of the research programme concept from Imre Lakatos.
- Evidence snippets:
  - Snippet 1 (score: 0.693)
    > The neurogenetic explanatory schema is particularly strong for Huntington's disease (Podvin et al., 2019).
    > However, in Alzheimer's disease and Parkinson's disease, the vast majority of cases are "sporadic," where neither family history, nor any one factor, is sufficient to explain disease onset, resulting in more complex explanations (Golde et al., 2013). Nevertheless, this programme considers that "the pathological cascades are likely to be more conserved than disparate" (p. 1847, (Golde et al., 2013) between familial and sporadic forms and there may also be shared mechanisms when "looking laterally across a spectrum of diseases to understand common pathological mechanisms downstream of the triggering proteinopathy" (p. 1849, Golde et al., 2013). Though Hardy recognised in 2006 that "no therapies for any neurologic or psychiatric disease have, as yet, been developed by this approach" (p. 8, (J. Hardy, 2006a)), he has frequently commented on results from different neurodegenerative disorders, discussing their "wider importance" for "mechanistic therapy for a neurodegenerative disease" (J. Hardy, 2018). Discovering the complexity of the pathological cascades of neurodegenerative diseases through the use of different methods has been a decades-long and ongoing challenge for Alzheimer's (De Strooper & Karran, 2016;Kepp et al., 2023;Rollo et al., 2023) and other diseases (Johnson et al., 2019).
    > My aim in what follows of this section is to provide a mechanistic understanding of the amyloid hypothesis as a Lakatosian research programme understood in the light of recent philosophy on mechanism within neuroscience. I will first focus on the positive heuristic of the amyloid hypothesis motivating claim-testing, before moving on to discuss the negative heuristic, i.e. motivating claimprotecting (Figure 2).

### [5] Pharmacochemical Strategies and Advances in Alzheimer's Disease Drug Development
- Authors: Jie Chen
- Year: 2025
- Venue: Highlights in Science, Engineering and Technology
- URL: https://www.semanticscholar.org/paper/a5b9e53e18b2322e4ee24624c57694ecce7e00e0
- DOI: 10.54097/qbjryc26
- Summary: Four widely accepted hypotheses on the pathogenesis of AD are summarized and the medicinal chemistry strategies for small-molecule drug discovery and development, based on the new research results in recent years are summarized.
- Evidence snippets:
  - Snippet 1 (score: 0.692)
    > Alzheimer's Disease (AD) is a common neurodegenerative disease, one of the main types of dementia, which concentrates on the elderly and is commonly known as Alzheimer's disease, and its clinical symptoms are mainly cognitive dysfunction, mental-behavioral abnormalities, memory loss, and impairment of self-care [1]. It is estimated that about 55 million people worldwide suffered from dementia in 2019, and this number is expected to increase to 139 million by 2050, while at the same time, the annual cost of dementia reached 1.3 trillion dollars in 2019, and is expected to increase to 2.8 trillion dollars by 2030. As the population ages, dementia is emerging as one of the leading causes of death. Therefore, studying the pathological mechanisms and drug targets of Alzheimer's disease to develop new and more efficient small molecule drugs has become a hot research topic nowadays, which is of great significance to further alleviate the symptoms and reduce the burden on the families, healthcare professionals, and even the society as a whole [2].
    > Currently, researchers have put forward various hypotheses on the pathogenesis of Alzheimer's disease, including the Aβ hypothesis, the Tau protein hypothesis, the neuroinflammation hypothesis, and the neurotransmitter imbalance hypothesis. These hypotheses have provided an important theoretical framework for the study of Alzheimer's disease pathomechanisms and promoted the exploration of relevant drug targets, such as Aβ proteins, Tau proteins, neurotransmitters, and microglia, etc. ( [3]). However, existing AD therapeutic drugs are still mainly focused on modulating excitatory neurotransmitters, which only serve to alleviate the disease and fail to stop its progression from the root cause. In addition, the complex pathological process of AD makes the identification of specific targets extremely difficult, and the yet to be elucidated pathomechanisms have also hindered the development of targeted drugs, compounded by the fact that the presence of the blood-brain barrier (BBB) may limit the transportation of drugs to the brain, further limiting the efficacy of the drugs [4].

### [6] Analysis and comparison of biomarkers for Alzheimer's disease
- Authors: Xin-Yi Zhou
- Year: 2024
- Venue: Theoretical and Natural Science
- URL: https://www.semanticscholar.org/paper/65cb731bc42a0ec417230b482cdd3718aab61920
- DOI: 10.54254/2753-8818/60/20241391
- Summary: This thesis finds that Alzheimer's disease (AD) can be treated using targeted approaches for different pathogenic mechanisms and proposes ideas to address the different mechanisms.
- Evidence snippets:
  - Snippet 1 (score: 0.686)
    > Abstract. Alzheimer's disease (AD), commonly known as dementia, is a neurodegenerative disease that causes memory and cognitive decline. Alzheimer's disease is a neurodegenerative disease that causes memory and cognitive deterioration in patients. 70% of the world's more than 50 million elderly patients suffer from Alzheimer's disease. Currently, scholars around the world mainly classify Alzheimer's disease (AD) patients into seven stages from onset to death. The pathogenesis of Alzheimer's disease (AD) has not yet been clarified by studies on different stages, and the main theories include the A- amyloid hypothesis and other theories such as abnormal phosphorylation of Tau protein. The A- amyloid hypothesis proposes that a type of A42 forms a large number of oligomers in the patient's brain due to misfolding and accumulation, which then develop into mature fibres and protofibrils, eventually accumulating into plaques that impede signalling between the patient's nerves and neurons to cause problems in the brain. The Tau protein theory proposes that it is due to over phosphorylation of pTau protein that disrupts the neuronal skeleton and forms neuronal fibre tangles (NFTS) causing impaired axonal transport to affect signalling. fibre tangles (NFTS) causing impaired axonal transport to affect signalling. This review provides an overview of the A amyloid hypothesis and the abnormal phosphorylation of Tau protein hypothesis, and compares their pathogenic mechanisms and proposes ideas to address the different mechanisms. This thesis finds that Alzheimer's disease (AD) can be treated using targeted approaches for different pathogenic mechanisms.

### [7] Integrating network, sequence and functional features using machine learning approaches towards identification of novel Alzheimer genes
- Authors: S. Jamal, Sukriti Goyal, A. Shanker, A. Grover
- Year: 2016
- Venue: BMC Genomics
- URL: https://www.semanticscholar.org/paper/336a38890491c6b20813d26e2a10ea1269e86ea5
- DOI: 10.1186/s12864-016-3108-1
- PMID: 27756223
- PMCID: 5070370
- Citations: 34
- Influential citations: 2
- Summary: This is the first comprehensive study of its kind for identification of putative Alzheimer-associated genes using machine learning approaches and it is proposed that such computational studies can improve the understanding on the core etiology of AD which could lead to the development of effective anti-Alzheimer drugs.
- Evidence snippets:
  - Snippet 1 (score: 0.682)
    > Alzheimer's disease (AD) is the most common neurological disease, accounting for 60-70 % of total dementia cases, affecting masses of people across the globe [1]. The growing incidences of this irreversible brain disease is due to lack of the effective treatment options, with the currently available drugs being able only to slow down the disease advancement and not halt it [2]. The neurodegenerative AD is characterized by short-term memory loss, challenges in completing daily activities, bafflement, problems in speaking and writing, changes in behavior and mood swings [3]. The socio-economic burden including medical expenses, costs associated with fulltime caregiving, etc. linked to the disease is huge which makes the disease as one of the most costly diseases [4]. Various hypothesis have been suggested to describe the cause of the disease, that include amyloid hypothesis, cholinergic hypothesis, tau hypothesis and genetic factors, yet the mechanism of the disease is poorly understood [5]. It has been proposed that genetic factors are mainly responsible for AD cases, and thus there have been many studies in quest for the genes associated with the disease and the unexplored principal genetic mechanisms [6].
    > A wide range of population surveys, genetic linkage studies and genome-wide association studies (GWAS) have been conducted to identify AD-associated genes and genetic mutations that alter with the expression of the genes in the brain. Apolipoprotein E (ApoE), Presenilin-1 (PSEN1) and Presenilin-2 (PSEN2), amyloid precursor protein (APP) and the linked mutations are some of the strongest risk factors that were observed to be associated with the brain disorder, Alzheimer's [7]. Researchers have proposed that alteration of the functions of any of these genes results in enhanced production of amyloid beta peptide (Aβ) in the brain, extracellular aggregation of which leads to loss of synaptic functions and neuronal cell death resulting in AD.

### [8] MFSD2A in health and disease: lysolipid transport, barrier physiology, and translational boundaries
- Authors: Jin-Heng Gan, Yang Chen, Lin Xin
- Year: 2026
- Venue: Molecular Biomedicine
- URL: https://www.semanticscholar.org/paper/fbc67667da19acb21fbb81a9421e30f69db80820
- DOI: 10.1186/s43556-026-00585-3
- PMID: 42809080
- PMCID: 13624201
- Summary: This framework identifies experimental priorities for linking MFSD2A activity to clinically informative phenotypes without extrapolating beyond current evidence, and clarifies which functions are established, which are tissue restricted, and which remain hypotheses.
- Evidence snippets:
  - Snippet 1 (score: 0.661)
    > Links between MFSD2A and chronic neurodegeneration remain biologically plausible but causally weak. Retinal and vascular studies in Alzheimer-type models report altered MFSD2A expression, AQP4, DHA-related readouts, or barrier phenotypes, and a small human study reported lower circulating MFSD2A in Alzheimer's disease [49,50,115,149,150,164]. These observations arise from different tissues, assays, and disease stages and cannot be combined into a single disease mechanism. Reduced DHA-containing phospholipids or BBB dysfunction may accompany neurodegeneration without proving that MFSD2A initiated the process.
    > A recent experimental amyotrophic lateral sclerosis study reported benefit from combined Mfsd2a overexpression and DHA supplementation in a defined model [165]. This finding is hypothesis-generating and disease specific; it does not establish a general nutritional rescue strategy, clinical efficacy, or a shared mechanism across neurodegenerative disorders. Current evidence does not establish MFSD2A as a causal driver, diagnostic biomarker, or validated therapeutic target in Alzheimer's disease or other chronic neurodegenerative disorders.

### [9] Amyloid β-Targeted Inhibitory Peptides for Alzheimer’s Disease: Current State and Future Perspectives
- Authors: Safura Jokar, Saeedeh Khazaei, Xaniar Esmailzadeh Gameshgoli, Mona Khafaji, Behnam Yarani et al.
- Year: 2020
- Venue: Alzheimer’s Disease: Drug Discovery
- URL: https://www.semanticscholar.org/paper/5eefc02000f84576e1cf86705333c9b654b366c3
- DOI: 10.36255/exonpublications.alzheimersdisease.2020.ch3
- Citations: 10
- Summary: This chapter provides an overview of the current knowledge on one such strategy, Aβ-targeted inhibitory peptides, actively explored as therapeutic strategies for Alzheimer’s disease.
- Evidence snippets:
  - Snippet 1 (score: 0.660)
    > ABSTRACT
    > Alzheimer’s disease is the most common irreversible neurodegenerative disorder. To date, there is no cure for Alzheimer’s disease. While multiple pathological mechanisms have been proposed for the onset and progression of Alzheimer’s disease, the hypothesis that attracted much attention is the amyloid hypothesis. The senile plaques that accumulate in the brain of Alzheimer’s disease patients are predominantly composed of beta amyloid (Aβ). Aβ deposition in the brain is thought to occur years before the emergence of clinical symptoms. The overproduction, aggregation, and fibrillation of Aβ, combined with reduced clearance, eventually lead to amyloid plaque formation and subsequent neurotoxicity. Hence, inhibition of Aβ aggregation and the promotion of Aβ clearance have been actively explored as therapeutic strategies for Alzheimer’s disease. This chapter provides an overview of the current knowledge on one such strategy, Aβ-targeted inhibitory peptides.

### [10] Unintended Effects of Cardiovascular Drugs on the Pathogenesis of Alzheimer’s Disease
- Authors: Jun Wang, Zhong Zhao, Emi Lin, Wei Zhao, X. Qian et al.
- Year: 2013
- Venue: PLoS ONE
- URL: https://www.semanticscholar.org/paper/f0d012192a1e46a557827780e7d53858574cc849
- DOI: 10.1371/journal.pone.0065232
- PMID: 23762322
- PMCID: 3675203
- Citations: 37
- Influential citations: 6
- Summary: This study screened 1,600 FDA approved drugs for β-amyloid (Aβ)-modifying activity and identified drugs that can potentially influence amyloid precursor protein processing and demonstrated that some hypertensive medication can differentially modulate Aβ, both in vitro and in vivo.
- Evidence snippets:
  - Snippet 1 (score: 0.649)
    > Alzheimer's disease (AD) is one of the most persistent and devastating disorders of old age, often leading to severe memory loss and functional impairment [1]. Its prevalence increases dramatically with aging. It is estimated that up to ,5 million people in the US currently have AD and it is projected that up to 14 million people will be affected by AD by the middle of this century.
    > AD is characterized neuropathologically by the accumulation of extracellular neuritic plaques composed of b-amyloid (Ab) protein, intracellular neurofibrillary tangles of hyperphosphorylated tau protein, and neuron loss [2]. A major hypothesis regarding the pathogenesis of AD is that abnormally elevated Ab content in the brain of AD patients is critical for the development of AD dementia. This hypothesis, commonly referred to as the ''amyloid hypothesis,'' suggests that increasing accumulation of Ab peptides promotes assembly of Ab proteins into neurotoxic, extracellular soluble oligomeric Ab aggregates that are largely responsible for cognitive deterioration and neuronal loss in AD [3][4][5][6][7][8][9]. Continuing recruitment of Ab peptides to oligomeric Ab aggregates leads to the formation of larger, insoluble Ab fibrils that contribute to the formation of AD type neuritic plaques in the brain [10]. The amyloid hypothesis is supported by substantial genetic [11] and preclinical evidence [12]. However, to date, clinical trials based on amyloid hypothesis with the target mechanism of reducing brain amyloid load have produced null results including the most recently completed antibody therapies (bapineuzamab), suggesting that the amyloid hypothesis and the optimal molecular targets or the optimal timing for intervention remains to be elucidated. Nonetheless, Ab remains to be one of the major disease modifying targets for AD drug discovery.
    > In addition to AD, the aged population is associated with higher risks for many chronic diseases, such as cardiovascular disorders, diabetes, arthritis, cancer or cognitive impairment. Many elderly individuals require one or more medications to treat and/or manage age-related chronic disease.

### [11] The Fourth Element Targeting Hypothesis of Alzheimer's Disease Pathogenesis and Pathophysiology
- Authors: R. Kuljiš
- Year: 2010
- Venue: Frontiers in Neurology
- URL: https://www.semanticscholar.org/paper/bc38acc6794d7e4909cf01a003f20fdd61c0d73b
- DOI: 10.3389/fneur.2010.00144
- PMID: 21188267
- PMCID: 3008923
- Citations: 3
- Summary: The 4EC is proposed to be the main target of both converging insults that over time cause sporadic forms of AD as postulated by the Danger Signal Hypothesis as well as the causes of inherited forms of neurodegeneration that resemble certain aspects of the clinical manifestations of sporadic AD.
- Evidence snippets:
  - Snippet 1 (score: 0.647)
    > Therefore, whether the hypothetical 4EC mechanism proposed here is universal, or unique to certain groups of patients, research aimed at testing the fact that the primary cellular target(s) of Alzheimer's disease is (are) unknown. It was this basic insight that led to this hypothesis, as part of the quest to determine the array of possible primary targets in neurodegenerative disorders, and their correlates at different levels of both conceptual and empirical analysis. The authors' work on the topics discussed herein was supported by the Brain-Mind Project, the United Through

### [12] Drug Discovery Based on Oxygen and Nitrogen (Non-)Heterocyclic Compounds Developed @LAQV–REQUIMTE/Aveiro
- Authors: Joana L. C. Sousa, Hélio M. T. Albuquerque, Artur M. S. Silva
- Year: 2023
- Venue: Pharmaceuticals
- URL: https://www.semanticscholar.org/paper/5f80d9e7d3e9e72c6bacc584f33327e4bf00b892
- DOI: 10.3390/ph16121668
- PMID: 38139794
- PMCID: 10747949
- Citations: 10
- Summary: An enlightened appraisal of all the bioactive compounds and their biological properties that were synthesized and studied by Artur Silva's research group in the last two decades is intended to provide.
- Evidence snippets:
  - Snippet 1 (score: 0.640)
    > Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder, quickly becoming a major healthcare and economic problem to deal with in modern societies. As for the majority of neurodegenerative diseases, AD is age-related and mainly affects people over 65 years old. In 2022, an estimated 32 million people worldwide suffered with AD, and this figure is expected to rise to 131.5 million in 2050 [55].
    > The multifactorial nature of AD has led to the discovery of several targets or target combinations in order to find effective treatments. Among many theories behind the disease pointing to glutamate excitotoxicity [56], oxidative stress [57], and biometal dyshomeostasis [58] as causative triggers of the underlying neurodegeneration (reviewed elsewhere [59]), the amyloid-β (Aβ) plaques and tau fibrils are hypothesized as the major contributing factors [60,61]. The mainstream concept though is clearly the amyloid cascade hypothesis (formulated by Hardy and Higgins), which explains that the aggregation of Aβ species causes neural death and eventually progression to AD [62,63].
    > The "cholinergic hypothesis" [64], which was the first and most studied approach describing AD pathophysiology, is based on compelling evidence mainly regarding three aspects: (i) the nucleus basalis of Meynert in the basal forebrain undergoes severe neurodegeneration in AD; (ii) the presynaptic cholinergic markers in the cerebral cortex are depleted seriously in AD; and (iii) cholinergic antagonists impair memory, whereas agonists alleviate cognitive deficits [65]. The theory behind the "cholinergic hypothesis" led to the development of not only several acetylcholinesterase inhibitors (AChEIs), but also many examples of dual-or multi-target compounds combining inhibitory effects in AChE with other AD-related targets (the so-called multi-target cholinesterase inhibitors) [65,66].
  - Snippet 2 (score: 0.639)
    > Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder, quickly becoming a major healthcare and economic problem to deal with in modern societies. As for the majority of neurodegenerative diseases, AD is age-related and mainly affects people over 65 years old. In 2022, an estimated 32 million people worldwide suffered with AD, and this figure is expected to rise to 131.5 million in 2050 [55].
    > The multifactorial nature of AD has led to the discovery of several targets or target combinations in order to find effective treatments. Among many theories behind the disease pointing to glutamate excitotoxicity [56], oxidative stress [57], and biometal dyshomeostasis [58] as causative triggers of the underlying neurodegeneration (reviewed elsewhere [59]), the amyloid-β (Aβ) plaques and tau fibrils are hypothesized as the major contributing factors [60,61]. The mainstream concept though is clearly the amyloid cascade hypothesis (formulated by Hardy and Higgins), which explains that the aggregation of Aβ species causes neural death and eventually progression to AD [62,63].
    > The "cholinergic hypothesis" [64], which was the first and most studied approach describing AD pathophysiology, is based on compelling evidence mainly regarding three aspects: (i) the nucleus basalis of Meynert in the basal forebrain undergoes severe neurodegeneration in AD; (ii) the presynaptic cholinergic markers in the cerebral cortex are depleted seriously in AD; and (iii) cholinergic antagonists impair memory, whereas agonists alleviate cognitive deficits [65]. The theory behind the "cholinergic hypothesis" led to the development of not only several acetylcholinesterase inhibitors (AChEIs), but also many examples of dual-or multi-target compounds combining inhibitory effects in AChE with other AD-related targets (the so-called multi-target cholinesterase inhibitors) [65,66].

### [13] Comparison of Tau and Amyloid-β Targeted Immunotherapy Nanoparticles for Alzheimer’s Disease
- Authors: Yara Mashal, H. Abdelhady, A. Iyer
- Year: 2022
- Venue: Biomolecules
- URL: https://www.semanticscholar.org/paper/739f04cb7cc88bf770c80e719114f9ed8a6f6345
- DOI: 10.3390/biom12071001
- PMID: 35883556
- PMCID: 9313310
- Citations: 16
- Influential citations: 1
- Summary: It is found that the search for a cure was mostly based on the amyloid-β hypothesis, with Aβ dysplasia emerging as the most confirmed and convincing therapeutic target.
- Evidence snippets:
  - Snippet 1 (score: 0.629)
    > Alzheimer’s disease (AD) is a rapidly growing global concern associated with the accumulation of amyloid-β plaques and intracellular neurofibrillary tangles in the brain combined with a high acetylcholinesterase activity. AD diagnosis is usually made too late, when patients have an extensive neuronal death, and brain damage is irreversible. Several therapeutic targets have been defined mainly related to two hypotheses of AD: the tau hypothesis and the amyloid-β hypothesis. Here, we intend to investigate and to compare different therapeutic approaches for AD, mainly based on nanoparticles (NPs) targeted at the brain and at the pathological hallmarks of the disease. We analyzed preclinical trials that have successfully improved drug bioavailability in the brain by using targeted nanocarriers towards either tau, amyloid-β, or both. We then compared these trials to find out which protein is more efficient in therapeutic targeting. We found that the search for a cure was mostly based on the amyloid-β hypothesis, with Aβ dysplasia emerging as the most confirmed and convincing therapeutic target. Targeted NPs have proven useful to enhance both the bioavailability and the performance of therapies against AD in animal models. A better understanding of AD mechanisms will help the successful application of targeted NPs for combined therapies.

### [14] Metallothionein and neurodegenerative diseases
- Authors: Yu-Feng Cheng, Yujia Zhao, Ce Chen, Feng Zhang
- Year: 2025
- Venue: Neural Regeneration Research
- URL: https://www.semanticscholar.org/paper/947ffea3a756c51fab7ed37efd8b1bd4bfea3ebe
- DOI: 10.4103/NRR.NRR-D-25-00011
- PMID: 40808411
- PMCID: 13452723
- Citations: 6
- Summary: The role of metal ions in the course of neurodegenerative diseases and the molecular mechanisms through which endogenous metallothionein ameliorates metal ion overload to alleviate neurodegenerative diseases are focused on.
- Evidence snippets:
  - Snippet 1 (score: 0.628)
    > Neurodegenerative diseases, which mainly include Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Wilson’s disease, and Huntington’s disease, are a group of disorders characterized by loss of neurons in the brain and spinal cord. However, the underlying pathogenetic mechanisms of these disorders remain unclear. The metal ion hypothesis is considered a possible cause of a variety of neurodegenerative diseases. This hypothesis posits that the homeostatic imbalance of metal ions leads to oxidative stress, neuroinflammation, excessive aggregation of pathological proteins, and other serious consequences in neurons. The powerful endogenous metal ion chelator metallothionein plays an important role in regulating metal ion homeostasis to alleviate neurodegenerative diseases. This article provides an overview of the pathogenesis of neurodegenerative diseases in relation to metal ions such as copper, iron, and zinc and the contribution of metallothionein to the regulation of metal ion homeostasis. The review focuses on the role of metal ions in the course of neurodegenerative diseases and the molecular mechanisms through which endogenous metallothionein ameliorates metal ion overload to alleviate neurodegenerative diseases. A thorough understanding of these molecular mechanisms can provide a theoretical foundation for the development of new therapeutic strategies, with the aim of more effectively treating these devastating diseases in the future.

### [15] Alternative hypotheses related to Alzheimer’s disease
- Authors: V. Cubinkova, B. Valachova, I. Uhrínová, V. Brezováková, T. Smolek et al.
- Year: 2018
- Venue: Bratislava Medical Journal
- URL: https://www.semanticscholar.org/paper/2e9c391efe8ac1f350edc0d593600d84c9045119
- DOI: 10.4149/BLL_2018_039
- PMID: 29663818
- Citations: 19
- Influential citations: 1
- Summary: In this review, some hypotheses such as amyloid and tau hypotheses, inflammatory processes, prion-like hypothesis, the hypothesis of oxidative stress, vascular and cholesterol hypothesis, the hypothesis of metal accumulation in the brain, cell cycle hypothesis, the hypothesis of impaired insulin signalization and another were proposed to explain the pathogenesis of this severe disorder.
- Evidence snippets:
  - Snippet 1 (score: 0.625)
    > Alzheimer’s disease represents the most common form of dementia and belongs to the group of neurodegenerative disorders characterized by progressive loss of neurons in the central nervous system. In the pathogenesis of Alzheimer’s disease several etiologic and pathogenic factors exist, which lead to the dysfunction of neurotransmitter systems and consequent cognitive decline. Last three decades have delivered a crucial progress leading to better understanding of Alzheimer’s disease, however, the exact mechanisms of pathology remain unclear. In this review, we summarize some hypotheses such as amyloid and tau hypotheses, inflammatory processes, prion-like hypothesis, the hypothesis of oxidative stress, vascular and cholesterol hypothesis, the hypothesis of metal accumulation in the brain, cell cycle hypothesis, the hypothesis of impaired insulin signalization and another, which were proposed to explain the pathogenesis of this severe disorder (Ref. 115). Text in PDF http://www.elis.sk/.

### [16] Overexpression of Swedish mutant APP in aged astrocytes attenuates excitatory synaptic transmission
- Authors: S. Katsurabayashi, Hiroyuki Kawano, Miyuki Ii, Sachiko Nakano, Chihiro Tatsumi et al.
- Year: 2016
- Venue: Physiological Reports
- URL: https://www.semanticscholar.org/paper/ef22ee75c73b0ef64ce894b3d79e378adf871a7c
- DOI: 10.14814/phy2.12665
- PMID: 26733247
- PMCID: 4760399
- Citations: 12
- Summary: Observations indicate that astrocytic expression of the mutant APP is involved in the downregulation of synaptic transmission with age.
- Evidence snippets:
  - Snippet 1 (score: 0.624)
    > Alzheimer's disease (AD) is a neurodegenerative disorder accompanied by progressive memory deterioration. Synaptic dysfunction likely represents a major hallmark of the early stage of AD (Selkoe 2002;Haass and Selkoe 2007). In particular, progressive loss of synapses aggravates memory impairment before the formation of senile plaques. Morphological abnormalities such as the loss of synapses, deposition of senile plaques, and changes in fibrillogenesis are major characteristics of the AD brain. There are three major hypotheses regarding the mechanism assumed to be the target for therapeutic drugs for AD: (1) the cholinergic hypothesis, (2) the amyloid hypothesis, and (3) the tau hypothesis. A cholinesterase inhibitor and an NMDA receptor antagonist are drugs ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of the American Physiological Society and The Physiological Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
    > clinically used to inhibit the progression of AD-type dementia (Rafii and Aisen 2015). On the other hand, the amyloid hypothesis has played a prominent role in explaining the pathology of AD. Recently, clinical trials have been envisaged on the basis of the Ab hypothesis regarding the drug targeting components of the amyloid pathway using passive/active antiamyloid immunotherapy (Schenk et al. 1999;Muhs et al. 2007;Ryan and Grundman 2009;Lemere and Masliah 2010;Winblad et al. 2012) and an inhibitor of the b-secretase cleaving enzyme (BACE)1 and BACE2 (Menting and Claassen 2014). In addition to the amyloid hypothesis, therapies targeting tau have been considered in immunotherapy based on the tau hypothesis (Lewis and Dickson 2015;Pedersen and Sigurdsson 2015;Sigurdsson 2016).
    > Amyloid precursor protein (APP), a type I transmembrane protein, is a fundamental element for production of the amyloid b (Ab) peptide (Goedert 1987).

### [17] Neuroimmunomodulation in Major Depressive Disorder: Focus on Caspase 1, Inducible Nitric Oxide Synthase, and Interferon-Gamma
- Authors: A. Inserra, C. Mastronardi, G. Rogers, J. Licinio, Ma-Li Wong
- Year: 2018
- Venue: Molecular Neurobiology
- URL: https://www.semanticscholar.org/paper/ecc3720ea7ec38b592c0ae0ecd89f4f2e42e6046
- DOI: 10.1007/s12035-018-1359-3
- PMID: 30306457
- PMCID: 6505498
- Citations: 91
- Influential citations: 6
- Summary: This work reviews the available pre-clinical and clinical evidence of an involvement of pro-inflammatory pathways in the pathogenesis, treatment, and remission of MDD and focuses on caspase 1, inducible nitric oxide synthase, and interferon gamma, three inflammatory systems dysregulated in MDD.
- Evidence snippets:
  - Snippet 1 (score: 0.621)
    > Major depressive disorder (MDD) is a psychiatric disorder with significant morbidity, mortality, disability, and economic burden worldwide [1,2]. In addition to the psychosocial and psychophysical dysfunctions associated with MDD, several conditions are often comorbid, including but not limited to obesity, type-2 diabetes, heart conditions, autoimmune diseases, neurodegenerative disorders, cancer, and intestinal conditions [3][4][5][6][7]. Multiple hypotheses have been formulated attempting to describe the elusive pathophysiology of MDD, including the monoamine hypothesis, the neurotrophic hypothesis, the glutamate hypothesis, the cytokine (or macrophage) hypothesis, and the microbiota-inflammasome hypothesis [8][9][10][11][12][13]. However, no single hypothesis seems to fully explain the onset, course, and remission of the disease. To complicate matters further, antidepressant drugs present numerous side effects and are effective only in a subset of patients [14][15][16]. Newer therapeutic strategies involve drugs acting on neuroplasticity-related pathways, gut microbiome modulation, and deep brain stimulation surgery [17][18][19]. Nevertheless, the quest for a better understanding of the molecular underpinnings of this disease represents an essential step in the identification of efficacious therapeutic strategies that could target the causal biological mechanisms of MDD.
    > Emerging evidence suggests that dysregulated neuroimmune pathways underlie depressive symptomatology in at least a subset of MDD patients [2,[20][21][22][23][24][25].

### [18] Progress in the development of new drugs in Alzheimer's disease
- Authors: A. Piau, F. Nourhashemi, C. Hein, C. Caillaud, B. Vellas
- Year: 2010
- Venue: The Journal of Nutrition, Health & Aging
- URL: https://www.semanticscholar.org/paper/8b69b020ca3771e2f7075f89220adf8e0c3b7eef
- DOI: 10.1007/s12603-011-0012-x
- PMID: 21267520
- PMCID: 12879621
- Citations: 44
- Summary: Taking into account AD complexity, it becomes clear that polypharmacology with drugs targeting different sites could be the future treatment approach and a majority of the recent drugs under evaluation seems to act on multiple targets.
- Evidence snippets:
  - Snippet 1 (score: 0.619)
    > AD is an increasingly important issue in our societies. Many clinical studies are ongoing with a lot of new compounds, but still no disease-modifying drug is available at this moment. Despite initially satisfying physiopathological hypothesis, no promising compound targeting tau pathology is under clinical evaluation, and no anti-amyloid drugs trial has had indisputable positive results. In fact, it is still not clear whether tau pathology and amyloid deposition are causative, final products, and even protective mechanism in the cascade of events. Alzheimer's disease is a complex multifactorial disorder, and there could be a need to reassess AD physiopathology to find new potential drug targets. Eventhough several drugs were developed by hazard, that is before their targets were known, time is counted and increasing the number of random clinical trials doesn't seem to be a cost-effective solution. Nevertheless, negative results of clinical trials enlighten researchers' abilities to improve their knowledge about drug actions and physiopathology and this is the reason why publication of negative data is such an important issue. According to some authors, the one protein, one drug, one disease hypothesis (a selective compound that acts on a single specific disease target to produce the desired clinical effects) used as the basis of most Alzheimer's disease therapy studies needs to be revised (252). They state that the linear approach of a candidate drug connected to a single target linked to a pathogenic pathway is too reductionist. Indeed, according to AD complexity, it becomes clear that polypharmacology with drugs targeting different sites could be the future treatment approach. In fact, many drugs already under evaluation seem to act on multiple targets. During several years preceding the diagnosis of dementia, there is a gradual cognitive decline with a continuum between the pre-dementia stage, still known as prodromal, now diluted within the general concept of mild cognitive impairment (MCI), and the other stages of the disease. This period where the symptoms may be underestimated, represent a "bridging" period of the disease before the cognitive impairment impacts on everyday activities. This highlights the need for the use of validated biomarkers in the development of innovative drugs starting at the early phases of the disease, when it could still be reversible.

### [19] Advancing translational research with the Semantic Web
- Authors: A. Ruttenberg, Tim Clark, W. Bug, M. Samwald, O. Bodenreider et al.
- Year: 2007
- Venue: BMC Bioinformatics
- URL: https://www.semanticscholar.org/paper/a363cd9efbc0b28d0c04241ad998b90207cbcb11
- DOI: 10.1186/1471-2105-8-S3-S2
- PMID: 17493285
- PMCID: 1892099
- Citations: 357
- Influential citations: 11
- Summary: A scenario that shows the value of the information environment the Semantic Web can support for aiding neuroscience researchers is presented and several projects by members of the HCLSIG are reported, illustrating the range ofSemantic Web technologies that have applications in areas of biomedicine.
- Evidence snippets:
  - Snippet 1 (score: 0.617)
    > In applying research to cure and prevent diseases, an integrated understanding across subspecialties becomes essential. Consider the study of neurodegenerative diseases such as Parkinson's Disease (PD), Alzheimer's Disease (AD), Huntington's Disease (HD), Amyotrophic Lateral Sclerosis (ALS), and others. Research on these diseases spans the disciplines of psychiatry, neurology, microscopic anatomy, neuronal physiology, biochemistry, genetics, molecular biology, and bioinformatics.
    > As an example, AD affects four million people in the U.S. population and causes great suffering and incurs enormous healthcare costs. Yet there is still no agreement on exactly how it is caused, or where best to intervene to treat it or prevent it. The Alzheimer Research Forum records more than twenty seven significant hypotheses [3] related to aspects of the etiology of AD, most of them combining supporting data and interpretations from multiple biomedical specialist areas.
    > One recent hypothesis on the cause of AD [4] illustrates the typical situation. The hypothesis combines data from research in mouse genetics, cell biology, animal neuropsychology, protein biochemistry, neuropathology, and other areas. Though commensurate with the "ADDL hypothesis" of AD etiology [5], essential claims in Lesné et al. conflict with those in other equally well-supported hypotheses, such as the amyloid cascade [6] and alternative amyloid cascade [7].
    > Consider also HD an inherited neurodegenerative disease. Although its genetic basis is relatively simple and it has been a model for autosomal dominant neurogenetic disorders for many years, [8], the mechanisms by which the disorder causes pathology are still not understood. In the case of PD, despite its having been studied for many decades, there are profound difficulties with some of the existing treatments [9,10], and novel or modified treatments are still being developed [11,12].
    > Increasingly, researchers recognize that Ad, PD, and HD share various features at the clinical [13], neural [14][15][16][17], cellular [18][19][20], and molecular levels [21,22].

## Notes

- This provider combines `search_papers_by_relevance` with `snippet_search`.
- No synthesis or second-stage model call is performed.

## Term Validation

No ontology term identifiers were found in this report.